Here, we have used immunohistochemistry and qRT-PCR assays to assess the correlation between CCL20 and FOXP3+ TIL expressions and the association with clinicopathological characteristics, analyzed the prognostic significance of CCL20 expression and FOXP3+ TILs infiltration in breast cancer, and deduced that CCL20/CCR6 may recruit FOXP3+ TILs to tumor sites, thereby promoting immune evasion in tumors. The gene discussed is CCL20; the disease is breast carcinoma.